CytomX Therapeutics, Inc. (CTMX)
CytomX Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
CytomX Therapeutics, Inc. (CTMX) is a Biotechnology company based in US with a market capitalization of $550M. Revenue declined 44.8% year-over-year and free cash flow was negative at -$75.8M. This page tracks CTMX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 119 employees · IPO Oct 8, 2015
Valuation
Valuation & price
$3.61as of May 17, 2026· -46.5% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
5.56
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$550M
Market cap
-44.8%
Revenue growth (YoY)
100.0%
Gross margin
-$75.8M
Free cash flow (USD)
-$132.8M
Net debt
Net cash position
63.4%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
1
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 7, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJun 22, 2026Filing
Equity Incentive Plan Amended
- Insider sellJun 17, 2026Filing
Insider Sell $5KOgden Christopher · Chief Financial Officer · $5K
- 8-K eventJun 3, 2026Filing
Collaboration Agreement Amendment
- Quarterly reportMay 7, 2026Filing
10-Q Filed
- 8-K eventMay 7, 2026Filing
Q1 2026 Financial Results
Questions
Frequently asked questions
What is CytomX Therapeutics, Inc.'s market cap?
CytomX Therapeutics, Inc. (CTMX) has a market capitalization of $550M.
What is CTMX's P/E ratio?
A meaningful P/E ratio is not available for CTMX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is CTMX's price-to-book (P/B) ratio?
CTMX trades at 5.56 times book value per share.
Are insiders buying CTMX stock?
SEC Form 4 filings show no open-market insider buys at CytomX Therapeutics, Inc. in the last 90 days (1 sell).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.